CJC-1295 with DAC is a synthetic growth-hormone-releasing hormone analogue designed with a drug-affinity complex that extends its persistence in experimental settings.
Available presentation: 5mg. Format: solution vial.
Molecule / type: GHRH analogue with DAC
Listed strength: 5mg
Format: solution vial
Page scope: product identification and research information
Published human and experimental studies have examined the molecule’s pharmacokinetics and its effects on growth hormone and IGF-1 signaling. NovaMeds presents this background for research context only, without treatment recommendations.
What strength is listed?
NovaMeds lists CJC-1295 DAC in a 5mg solution vial presentation.
What does DAC refer to?
DAC refers to the drug-affinity complex used to prolong the molecule’s association with circulating albumin, affecting its pharmacokinetic profile.
Where can I review quality information?
See the Quality and Product Verification pages for the NovaMeds documentation framework.